Source: Υπουργείο Υγείας (CY) Revision Year: 2019 Publisher: Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
Cinnaron 25 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White, round, flat, scored tablets with Remedica’s logo on one side. The tablet can be divided into equal doses. |
Each tablet contains 25 mg cinnarizine.
Excipients with known effect:
Each tablet contains 138 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cinnarizine |
Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction. |
| List of Excipients |
|---|
|
Povidone |
PVC/Aluminium blisters. Pack sizes of 50 and 500 tablets.
PP containers with PE closures. Pack sizes of 50, 500 and 1000 tablets.
Not all pack sizes may be marketed.
Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
8557
Date of first authorization: 20 November 1982
Date of latest renewal: 20 March 2009
| Drug | Countries | |
|---|---|---|
| CINNARON | Cyprus, Estonia, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
